The South Korean government said Tuesday that it would invest 98.2 billion won in improving its evaluation guidelines for new biopharmaceutical products over the next 10 years. The plans came as part of the latest agenda set by a special pan-government biotechnology committee led by the Ministry of Science, ICT and Future Planning.